C
Creoptix
Develops next generation instruments for the high-sensitivity analysis of label-free molecular interactions
About Creoptix
Creoptix AG specializes in advanced biosensor technology designed for drug discovery and life sciences. Utilizing proprietary Grating Coupled Interferometry (GCI) technology, the Creoptix WAVE system offers unparalleled resolution in signal and time, enabling accurate measurement of kinetic rates, affinity constants, and biomolecular interactions even at low analyte concentrations. The company serves research laboratories in both academic and industrial settings, providing tools that streamline workflows and enhance data precision. Operating in the biosensor market, Creoptix generates revenue through the sale of its WAVE systems and accompanying software, WAVEcontrol. The business model focuses on delivering high-value, cutting-edge technology to researchers who require precise and reliable data for their experiments.
Source: Dealroom company dataAt a glance
- Founded
- 2009
- Headquarters
- Zurich, Switzerland
- Sector
- Transportation
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
ZKB - Zürcher Kantonalbank
StartAngels
Series B and later2 investors entered at this stage
Swisscanto Invest
Waters Corporation
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Creoptix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Creoptix on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.